Literature DB >> 16097435

Topoisomerase II alpha expression in breast ductal invasive carcinomas and correlation with clinicopathological variables.

A Kalogeraki1, P Ieromonachou, M Kafousi, E Giannikaki, T Vrekoussis, O Zoras, D Tsiftsis, G Delides, E Stathopoulos.   

Abstract

Topoisomerase II alpha (topo IIa) is an enzyme that in normal cells is expressed predominantly in the S/G2/M-phase of the cell cycle. In malignant cells, in vitro studies have indicated that the expression of topo II alpha is both higher and less dependent on the proliferation state in the cell. To study the expression of topo IIa and the relationship between that expression-and other variables in cases of breast ductal invasive carcinomas, 50 fine-needle aspiration biopsies were performed from the same number of female patients, diagnosed cytologically and confirmed histologically after surgery. The same cases were studied immunocytochemically using monoclonal antibodies to topo IIa and Her2/neu (CB11) by the alkaline phosphatase method (APAAP). Topo IIa was found in 32 cases (64%) of the carcinomas studied. An overexpression between topo IIa and Her2/neu was found (p < 0.005). A relationship between topo IIa expression, histological grade and lymph node status (LNs) was also found (p < 0.005). Increased topo IIa expression seems to be related to an aggressive form of breast cancer featuring Her2 amplification and lymph node metastasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16097435

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  3 in total

1.  Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer.

Authors:  Mehmet Salih Iyikesici; Gul Basaran; Faysal Dane; Meltem Ekenel; P Fulden Yumuk; Devrim Cabuk; Mehmet Teomete; N Serdar Turhal
Journal:  Int J Clin Exp Med       Date:  2014-05-15

Review 2.  HER2-positive breast cancer: current and future treatment strategies.

Authors:  Ryan H Engel; Virginia G Kaklamani
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Mutual regulation of MDM4 and TOP2A in cancer cell proliferation.

Authors:  Tao Liu; Hailong Zhang; Sha Yi; Lubing Gu; Muxiang Zhou
Journal:  Mol Oncol       Date:  2019-02-04       Impact factor: 6.603

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.